Fig. 4
Effect of tanimilast on LPS-moDC phenotype. moDCs were pre-treated or not (-) with either tanimilast (TAN) or budesonide (BUD) (both at 10−7 M) for 1 h and subsequently stimulated or not with LPS for 24 h. The surface expression of regulatory markers PD-L1, ILT3/CD85k (A) and of maturation markers MHC-I (B), CD80, CD86 (C) were evaluated by FACS analysis. Data are expressed as the mean ± SEM (n = 3) of the percentage of positive cells (left y axis) and of the Median Fluorescence Intensity (MFI) (right y axis). (A–C) #P < 0.05 versus (-) and *P < 0.05 versus LPS by one-way ANOVA with Dunnett’s post-hoc test. (D) Correlation between CD86/CD80 ratios and % of single IL-13+ T cells induced by LPS-moDCs (black dots), TAN-LPS-moDCs (dark grey dots) or BUD-LPS-moDCs (light grey dots) from 3/4 donors (R2 = 0.7325; Spearman r = 0.8559, ***P = 0.0008)